Taysha Gene Therapies, Inc.
$6.46
▲
1.39%
2026-04-21 09:55:01
www.tayshagtx.com
NMS: TSHA
Explore Taysha Gene Therapies, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.85 B
Current Price
$6.46
52W High / Low
$6.5 / $1.13
Stock P/E
—
Book Value
$0.87
Dividend Yield
—
ROCE
-34.88%
ROE
-68.45%
Face Value
—
EPS
$-0.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
99
Beta
1.08
Debt / Equity
28.41
Current Ratio
12.23
Quick Ratio
12.23
Forward P/E
-11.02
Price / Sales
131.98
Enterprise Value
$1.04 B
EV / EBITDA
-9.51
EV / Revenue
106.44
Rating
Strong Buy
Target Price
$11.57
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 2. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 3. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 4. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 5. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 6. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 7. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.49 M | 0 M | 1.99 M | 2.3 M | 2.02 M | — |
| Operating Profit | -28.3 M | -34.02 M | -26.75 M | -21.42 M | -19.93 M | — |
| Net Profit | -27.85 M | -32.73 M | -26.88 M | -21.53 M | -18.79 M | — |
| EPS in Rs | -0.1 | -0.11 | -0.09 | -0.07 | -0.07 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.77 M | 8.33 M | 15.45 M | 2.5 M |
| Operating Profit | -110.5 M | -86.62 M | -71.37 M | -126.03 M |
| Net Profit | -109 M | -89.3 M | -111.57 M | -166.01 M |
| EPS in Rs | -0.38 | -0.31 | -0.39 | -0.58 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 343.32 M | 160.36 M | 172.73 M | 126.28 M |
| Total Liabilities | 96.38 M | 88.84 M | 97.79 M | 125.33 M |
| Equity | 246.94 M | 71.53 M | 74.94 M | 0.95 M |
| Current Assets | 324.65 M | 142.13 M | 149.87 M | 96.42 M |
| Current Liabilities | 26.55 M | 26.23 M | 36.76 M | 62.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -93.09 M | -81.22 M | -73.02 M | -88.39 M |
| Investing CF | -0.6 M | -0.36 M | -7.35 M | -24.93 M |
| Financing CF | 274.59 M | 76.68 M | 136.39 M | 52.1 M |
| Free CF | -93.83 M | -81.6 M | -80.39 M | -113.26 M |
| Capex | -0.74 M | -0.37 M | -7.37 M | -24.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -46.07% | 517.55% | — | — |
| Earnings Growth % | 19.96% | 32.8% | — | — |
| Profit Margin % | -1071.62% | -722.06% | -6635.25% | — |
| Operating Margin % | -1039.49% | -461.94% | -5037.05% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1055.45% | -680.84% | -6436.61% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.